Clinical trials: Cephalalgia
Migraine
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
- Trial name
- AURORA (NCT06602479)
- Testing
- MEDI0618
- Where
- 71 sites in United States, Czechia and 6 more
- Volunteers
- 309 people
- Sponsor
- AbbVie
Migraine Headache
A Study of LY2951742 in Participants With Migraine
To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in migraineurs with or without aura during 3 months of treatment.
- Trial name
- NCT01625988
- Testing
- LY2951742
- Where
- 37 sites in United States
- Volunteers
- 218 people
- Sponsor
- Eli Lilly and Company
Headache
Safety and Efficacy Predimenol for Headache
This is a prospective, double-blind, placebo-controlled and randomized study aimed to obtain a description of the efficacy and safety of Predimenol in alleviating headache.
- Trial name
- NCT06558006
- Testing
- Predimenol tablet
- Where
- 2 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dexa Medica Group
Migraine
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
The purpose of this study is: 1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract 2. To assess recurrence rate between two group 3.
- Trial name
- NCT00821483
- Testing
- Frovatriptan
- Volunteers
- 298 people
- Sponsor
- SK Chemicals Co., Ltd.
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Fatigue, Stress
The U.S. Embryologist Fatigue Study
The purpose of the study is to determine physical and mental health issues of U.S. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism…
- Conditions
- Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain
- Trial name
- FUSE (NCT05326802)
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- TMRW Life Sciences
Migraine With Aura, Migraine Without Aura
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT03874832
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Short Lasting Unilateral Neuralgiform Headache Attacks
Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
- Trial name
- NCT04905121
- Testing
- Psilocybin
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- Beckley Psytech Limited
Migraine Disorders
Safety Tolerability and Pharmacokinetics of ALD403
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT01579383
- Testing
- ALD403, Sumatriptan
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- NCT06004388
- Testing
- Click Digital Therapeutic
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Click Therapeutics, Inc.
Migraine Disorders
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken…
- Trial name
- NCT00792636
- Testing
- sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
- Where
- 49 sites in United States
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders, Headache Disorders
Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone
This study is conducted at the Henry Ford Health System with Lifegraph's behavioral monitoring technology, to examine the relation between migraine attacks and behavioral and environmental changes as detected from the smartphone…
- Conditions
- Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases
- Trial name
- Migraine (NCT03762902)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lifegraph Ltd.
Migraine Disorders
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
- Trial name
- NCT05342493
- Testing
- Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the prevention of migraine.
- Trial name
- NCT05399485
- Testing
- Rimegepant
- Where
- 44 sites in Japan
- Volunteers
- 496 people
- Sponsor
- Pfizer
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Headache, Migraine
Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain
The purpose of this study is to evaluate the short-term effectiveness of combined occipital and supraorbital transcutaneous nerve stimulation in reducing migraine related pain.
- Trial name
- NCT02438553
- Testing
- OSTNS Neurostimulator
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Neurolief Ltd.
Migraine
A Controlled Trial of Erenumab in Migraine Prevention
The purpose of this study was to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM).
- Trial name
- NCT03812224
- Testing
- Erenumab
- Where
- 41 sites in Japan
- Volunteers
- 261 people
- Sponsor
- Amgen
Migraine Disorders
A Study of Lasmiditan in Participants With Migraine
The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.
- Trial name
- NCT03247790
- Testing
- Lasmiditan
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pain, Migraine Disorders
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04427429 in healthy women.
- Trial name
- NCT01511497
- Testing
- PF-04427429, Normal saline
- Where
- 3 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly [except for a loading dose of 675 mg for CM patients] or at 675 mg every 3 months) for the preventive…
- Trial name
- NCT03303105
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.